KLOW Peptide Blend: Ingredients, Uses & Dosing

KLOW is a multi-peptide research blend combining GHK-Cu, BPC-157, TB-500, and KPV, four highly studied peptides known for their roles in cellular repair, inflammation modulation, and tissue regeneration. This synergistic formulation is intended exclusively for controlled scientific investigation in in vitro and in vivo preclinical models.

2026 update: None of KLOW’s component peptides are FDA-approved for human use. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee narrowly voted to recommend BPC-157, TB-500, and KPV for the 503A compounding list, but they have not been added to that list, and further rulemaking would be required. These remain research-use-only compounds.

Research Application

Cellular Repair and Regeneration

KLOW includes BPC-157, a pentadecapeptide derived from gastric proteins, and TB-500, a thymosin β4 fragment. Both are widely used in preclinical models to promote fibroblast migration, tissue remodeling, and angiogenesis. In murine wound and tendon injury models, these peptides accelerate cellular outgrowth, extracellular matrix formation, and vascularization [1] [2].

GHK-Cu, a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine), is studied for its regulatory effects on wound healing, skin regeneration, and tissue remodeling, often attributed to its ability to upregulate metalloproteinases and suppress oxidative damage [3].

Anti-Inflammatory and Immune Modulation

KPV, a C-terminal tripeptide fragment of alpha-MSH (Lys-Pro-Val), is included for its potent anti-inflammatory properties. It has been shown in rodent colitis and dermatitis models to reduce TNF-α, IL-6, and NF-κB expression, indicating suppression of key inflammatory cascades [4].

Together with BPC-157, also known to modulate inflammatory cytokine activity, KLOW is suited for research involving immune response modulation and epithelial barrier integrity under inflammatory stress.

Angiogenesis and Microvascular Studies

Both TB-500 and BPC-157 are associated with enhanced angiogenesis and improved microcirculation in ischemic tissue. GHK-Cu contributes by stimulating VEGF production and endothelial cell proliferation. These effects have been documented in cardiovascular and dermal injury models, supporting their use in vascular and perfusion-based research [5].

This makes KLOW applicable in experimental studies on endothelial function, ischemic damage, and post-injury vascular remodeling.

Epithelial Barrier and Gut Models

In gut-related research, KPV and BPC-157 have shown protective effects in models of intestinal inflammation and permeability disruption. KPV exerts action through melanocortin receptor pathways, while BPC-157 supports tight junction integrity. This combination allows KLOW to be used in advanced GI, epithelial barrier, and microbiome interaction studies [6].

Reconstitution and dosing

KLOW is typically reconstituted with Bacteriostatic water in various concentrations. A standard, simple reconstitution uses 2.5ml Bacteriostatic water with dosing at 5 ticks on an insulin syringe. Using 2.5ml Bacteriostatic water in KLOW containing 50mg GHK-Cu, 10mg KPV, 10mg BPC-157 and 10mg TB-500, 5 ticks would yield 1mg GHK-Cu, 200mcg KPV, 200mcg BPC-157 and 200mcg TB-500. Most users aim for 1 to 2mg GHK-Cu daily.

For our free Peptide Calculator, CLICK HERE. Research-grade KLOW is available from WellnessPeptides.

Referenced Citations

1. Sikiric P, et al. “BPC 157 and organ/tissue healing mechanisms.” PubMed
   Source: Regulatory Peptides – Tissue regeneration and inflammation studies.
2. Goldstein AL, et al. “Thymosin beta-4 and tissue repair.” PubMed
   Source: Annals of the New York Academy of Sciences – Role in cell migration and repair.
3. Pickart L, et al. “GHK-Cu peptide regulation of gene expression.” PubMed
   Source: BioMed Research International – Skin and gene regulation effects.
4. Getting SJ. “KPV peptide in inflammation models.” PubMed
   Source: European Journal of Pharmacology – Cytokine modulation and inflammation control.
5. Strandjord TP, et al. “GHK and copper peptide signaling in angiogenesis.” PubMed
   Source: Journal of Investigative Dermatology – VEGF stimulation by GHK-Cu.
6. Mounsey KE, et al. “Anti-inflammatory mechanisms of KPV.” PubMed
   Source: Peptides – MC1R-mediated anti-inflammatory effects.

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.